Literature DB >> 34790859

Occurrence of Type 1 Diabetes in A Patient Enrolled in An Immunotherapy Combination Phase 1 Clinical Trial: A Case Study.

Sheena Charles1, Anna Poullard1.   

Abstract

Advances in cancer immunotherapy treatments have shown promising results in patients with metastatic malignancy who have been refractory to prior treatments. Immune checkpoint inhibitors such as pembrolizumab in combination with other systemic agents may unleash immune-related adverse events (irAEs). Immunotherapy-induced Type 1 diabetes is rare; however, if left undiagnosed, it may cause life-threatening metabolic endocrinopathies. Advanced practice registered nurses are in a unique position to recognize and identify this irAE and in doing so can provide pathways for early diagnosis and treatments, thus leading to improved clinical and patient outcomes. Copyright:
© 2021 Ann & Joshua Medical Publishing Co. Ltd.

Entities:  

Keywords:  Immune checkpoint inhibitors; Type 1 diabetes; immunotherapy

Year:  2021        PMID： 34790859      PMCID： PMC8522589          DOI： 10.4103/apjon.apjon-2122

Source DB:  PubMed          Journal:  Asia Pac J Oncol Nurs        ISSN： 2347-5625


  10 in total

1.  Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.

Authors:  Venessa H M Tsang; Rachel T McGrath; Roderick J Clifton-Bligh; Richard A Scolyer; Valerie Jakrot; Alexander D Guminski; Georgina V Long; Alexander M Menzies
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

Review 2.  Expert opinion on immunotherapy induced diabetes.

Authors:  Sarra Smati; Perrine Buffier; Benjamin Bouillet; Françoise Archambeaud; Bruno Vergès; Bertrand Cariou
Journal:  Ann Endocrinol (Paris)       Date:  2018-07-25       Impact factor: 2.478

Review 3.  Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.

Authors:  J A Harrington; T C Hernandez-Guerrero; B Basu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-11-03       Impact factor: 4.126

4.  Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.

Authors:  Matthew A Smith-Cohn; David Gill; Benjamin N Voorhies; Neeraj Agarwal; Ignacio Garrido-Laguna
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

5.  Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.

Authors:  Marie-Léa Gauci; Philippe Boudou; Barouyr Baroudjian; Tiphaine Vidal-Trecan; Laetitia Da Meda; Isabelle Madelaine-Chambrin; Nicole Basset-Seguin; Martine Bagot; Cécile Pages; Samia Mourah; Matthieu Resche-Rigon; Sylvine Pinel; Marion Sassier; Franck Rouby; Pirayeh Eftekhari; Céleste Lebbé; Jean-François Gautier
Journal:  Cancer Immunol Immunother       Date:  2018-05-28       Impact factor: 6.968

6.  A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.

Authors:  Young Kwang Chae; Lauren Chiec; Nisha Mohindra; Ryan Gentzler; Jyoti Patel; Francis Giles
Journal:  Cancer Immunol Immunother       Date:  2016-10-19       Impact factor: 6.968

7.  Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.

Authors:  Olivier Peyrony; Sami Ellouze; Jean-Paul Fontaine; Inna Mohamadou; Lara Zafrani
Journal:  Am J Emerg Med       Date:  2019-10-14       Impact factor: 2.469

Review 8.  Advances in immunotherapy of type I diabetes.

Authors:  Qianqian Ni; Ngoc B Pham; Wilson S Meng; Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-12-07       Impact factor: 15.470

9.  Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.

Authors:  James Luke Godwin; Shuchie Jaggi; Imali Sirisena; Pankaj Sharda; Ajay D Rao; Ranee Mehra; Colleen Veloski
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

Review 10.  Immune checkpoint inhibitors and diabetes: Mechanisms and predictors.

Authors:  Natalie Youssef; Mohamed Noureldein; Georges Daoud; Assaad A Eid
Journal:  Diabetes Metab       Date:  2020-09-30       Impact factor: 6.041
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.